769 related articles for article (PubMed ID: 27186360)
21. Incretin effect: GLP-1, GIP, DPP4.
Kazafeos K
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of incretin secretion by dietary lipid: is it dose dependent?
Yoder SM; Yang Q; Kindel TL; Tso P
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G299-305. PubMed ID: 19520739
[TBL] [Abstract][Full Text] [Related]
23. Biology of incretins: GLP-1 and GIP.
Baggio LL; Drucker DJ
Gastroenterology; 2007 May; 132(6):2131-57. PubMed ID: 17498508
[TBL] [Abstract][Full Text] [Related]
24. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
25. Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion.
Yan S; Conley JM; Reilly AM; Stull ND; Abhyankar SD; Ericsson AC; Kono T; Molosh AI; Kubal CA; Evans-Molina C; Ren H
Cell Rep; 2022 Jan; 38(1):110179. PubMed ID: 34986353
[TBL] [Abstract][Full Text] [Related]
26. Update on incretin hormones.
Phillips LK; Prins JB
Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
[TBL] [Abstract][Full Text] [Related]
27. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
28. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
Matuszek B; Lenart-Lipińska M; Nowakowski A
Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
[TBL] [Abstract][Full Text] [Related]
29. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
30. Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity.
Seino Y; Yamazaki Y
J Diabetes Investig; 2022 Jul; 13(7):1122-1128. PubMed ID: 35452190
[TBL] [Abstract][Full Text] [Related]
31. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
32. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
33. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
[TBL] [Abstract][Full Text] [Related]
34. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
João AL; Reis F; Fernandes R
Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice.
Pacini G; Ahrén B
Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28611149
[TBL] [Abstract][Full Text] [Related]
36. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
37. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
38. The enteroinsular axis in dipeptidyl peptidase IV-negative rats.
Pederson RA; Kieffer TJ; Pauly R; Kofod H; Kwong J; McIntosh CH
Metabolism; 1996 Nov; 45(11):1335-41. PubMed ID: 8931636
[TBL] [Abstract][Full Text] [Related]
39. Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight.
Wang F; Yoder SM; Yang Q; Kohan AB; Kindel TL; Wang J; Tso P
Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(10):G807-15. PubMed ID: 26336929
[TBL] [Abstract][Full Text] [Related]
40. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]